{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:06:36Z","timestamp":1790643996944,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.semarthrit.2016.07.014","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T00:25:02Z","timestamp":1469924702000},"page":"488-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies"],"prefix":"10.1016","volume":"46","author":[{"given":"Sabrina","family":"Anh-Tu Hoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.07.014_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2990.2010.01153.x","article-title":"Review: an update on inflammatory and autoimmune myopathies","volume":"37","author":"Dalakas","year":"2011","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","article-title":"Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis","volume":"61","author":"Danieli","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2006.058644","article-title":"Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies","volume":"66","author":"Barbasso Helmers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib13","first-page":"588","article-title":"Efficacy and safety of the combined treatment with intravenous immunoglobulin and oral glucocorticoid in the elderly with dermatomyositis","volume":"27","author":"Tian","year":"2008","journal-title":"Chin J Geriatr"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib14","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib15","first-page":"29","article-title":"High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels","volume":"10","author":"Gottfried","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.autrev.2014.08.023","article-title":"Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2007.07.009","article-title":"Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis\/systemic lupus erythematosus overlap syndrome and tuberculosis","volume":"125","author":"Luzi","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MAJ.0000000000000232","article-title":"Myocarditis successfully treated with intravenous immunoglobulin in a patient with systemic lupus erythematous and myositis","volume":"347","author":"Barnado","year":"2014","journal-title":"Am Je Med Sci"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/keg250","article-title":"Inclusion body myositis evolving in systemic lupus erythrematosus? A case report","volume":"42","author":"Massawi","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib21","first-page":"393","article-title":"Inflammatory myopathy with initial respiratory muscles involvement and rheumatoid arthritis","volume":"74","author":"Hunter","year":"2014","journal-title":"Medicina"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/03009742.2013.868510","article-title":"Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis","volume":"43","author":"Mauhin","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib23","doi-asserted-by":"crossref","first-page":"R149","DOI":"10.1186\/ar4332","article-title":"Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome","volume":"15","author":"Marie","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00415-004-0449-5","article-title":"The long-term outcome of anti-Jo-1-positive inflammatory myopathies","volume":"251","author":"Spath","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1378\/chest.11-2437","article-title":"A 79-year-old man with dyspnea, dysphagia, and weakness","volume":"142","author":"Riveiro-Barciela","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib26","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2169\/internalmedicine.54.3597","article-title":"Rapidly progressive interstitial lung disease associated with dermatomyositis treated with combination of immunosuppressive therapy, direct hemoperfusion with a polymyxin B Immobilized Fiber column and intravenous immunoglobulin","volume":"54","author":"Takai","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jbspin.2009.02.004","article-title":"Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome","volume":"76","author":"Hervier","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2007.01.004","article-title":"Paraneoplastic myopathy: response to intravenous immunoglobulin","volume":"17","author":"Sampson","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00296-013-2910-1","article-title":"Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort","volume":"34","author":"Neri","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s10067-006-0337-8","article-title":"Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis","volume":"26","author":"Aslanidis","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1346-8138.1996.tb04027.x","article-title":"Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin","volume":"23","author":"Kikuchi-Numagami","year":"1996","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib32","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib33","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib37","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"Dobloug","year":"2012","journal-title":"ClinExp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0028-3843(14)60062-1","article-title":"Inclusion body myositis: therapeutic approaches. A case report","volume":"45","author":"Kierdaszuk","year":"2011","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib39","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.7326\/0003-4819-134-12-200106190-00031","article-title":"Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis","volume":"134","author":"Mukunda","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mus.23895","article-title":"Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia","volume":"48","author":"Pars","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-009-1290-z","article-title":"Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?","volume":"32","author":"Recher","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","article-title":"Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin","volume":"43","author":"Soueidan","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/1744666X.2013.842467","article-title":"Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives","volume":"9","author":"Schmidt","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib44","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1002\/art.37692","article-title":"Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and beta-amyloid in the muscle","volume":"64","author":"Zschuntzsch","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib46","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-857X(05)70350-1","article-title":"Classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"23","author":"Rider","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib48","first-page":"111","article-title":"Intravenous immunoglobulin therapy in juvenile dermatomyositis","volume":"38","author":"Tsai","year":"1997","journal-title":"Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib49","first-page":"2498","article-title":"Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety","volume":"27","author":"Al-Mayouf","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0002-9343(91)90010-U","article-title":"Treatment of dermatomyositis with intravenous gammaglobulin","volume":"91","author":"Lang","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib51","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/j.1365-2133.2007.07891.x","article-title":"Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin","volume":"156","author":"Amano","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jbspin.2012.07.001","article-title":"Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy","volume":"80","author":"Touimy","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12013-014-9833-7","article-title":"Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis","volume":"69","author":"Imataka","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-207579","article-title":"Juvenile polymyositis with unremitting pain and progressive loss of motor and bulbar function on a background of sickle cell disease","volume":"2015","author":"Bali","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/35.10.1029","article-title":"Failure of first-line therapy with intravenous immunoglobulin in a child with scleromyositis","volume":"35","author":"Abinun","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib56","first-page":"1979","article-title":"Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis","volume":"137","author":"Breems","year":"1993","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1442-200x.1999.01132.x","article-title":"Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis","volume":"41","author":"Kokori","year":"1999","journal-title":"Pediatr Int"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","article-title":"Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids","volume":"156","author":"Levy","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib59","first-page":"219","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib60","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.12746","article-title":"Successful treatment with intravenous high-dose immunoglobulin for cardiomyopathy in dermatomyositis complicated with rapid progressive interstitial pneumonia","author":"Yoshimatsu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib63","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","article-title":"Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center","volume":"69","author":"Femia","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib64","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/jdv.12223","article-title":"Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease","volume":"28","author":"Bounfour","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib65","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1346-8138.1999.tb02026.x","article-title":"Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions","volume":"26","author":"Sadayama","year":"1999","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib66","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.oooo.2014.05.026","article-title":"Oral lichen planus in a dermatomyositis patient that resolved after intravenous immunoglobulin therapy","volume":"118","author":"Geist","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaad.2015.03.047","article-title":"Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis","volume":"73","author":"Galimberti","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib68","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jaad.2008.09.051","article-title":"Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin","volume":"60","author":"Penate","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2332\/allergolint.55.199","article-title":"Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis","volume":"55","author":"Murota","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib72","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.annder.2013.04.083","article-title":"Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case","volume":"140","author":"Girard","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib73","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2169\/internalmedicine.42.1253","article-title":"Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A","volume":"42","author":"Shimojima","year":"2003","journal-title":"Intern Medicine"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MAJ.0b013e318031b122","article-title":"A case of hypomyopathic dermatomyositis associated with rapid progressive interstitial pneumonia resistant to multi-immunosuppressive therapy","volume":"333","author":"Tsuda","year":"2007","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00003081-199906000-00021","article-title":"Clinical uses of intravenous immunoglobulin in pregnancy","volume":"42","author":"Clark","year":"1999","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib76","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2005.01.002","article-title":"Myasthenia gravis: management issues during pregnancy","volume":"121","author":"Ferrero","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib77","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10072-009-0188-6","article-title":"Good maternal and fetal outcomes of predominantly sensory Guillain\u2013Barre syndrome in pregnancy after intravenous immunoglobulin","volume":"31","author":"Matsuzawa","year":"2010","journal-title":"Neurol Sci"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib78","first-page":"1798","article-title":"Juvenile dermatomyositis and pregnancy: report and literature review","volume":"19","author":"Pinheiro Gda","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib79","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3904\/kjim.2003.18.3.196","article-title":"Dermatomyositis developing in the first trimester of pregnancy","volume":"18","author":"Park","year":"2003","journal-title":"Kor J Intern Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/art.20913","article-title":"Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy","volume":"53","author":"Mosca","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2 Pt2","key":"10.1016\/j.semarthrit.2016.07.014_bib81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.AOG.0000253244.45837.7c","article-title":"Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy","volume":"109","author":"Williams","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib82","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3899\/jrheum.080389","article-title":"Respiratory muscle weakness with dermatomyositis during pregnancy: successful treatment with intravenous immunoglobulin therapy","volume":"35","author":"Nozaki","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00296-009-1166-2","article-title":"Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis","volume":"31","author":"Linardaki","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib84","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib85","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199412153312409","article-title":"Transmission of viral infections through intravenous immune globulin","volume":"331","author":"Schiff","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib86","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/0003-4819-121-4-199408150-00014","article-title":"Aseptic meningitis and intravenous immunoglobulin therapy","volume":"121","author":"Scribner","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib87","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib88","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N","article-title":"Complications of intravenous gammaglobulin in neuromuscular and other diseases","volume":"19","author":"Bertorini","year":"1996","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib89","first-page":"83","article-title":"Pulmonary and renal toxicity of intravenous immunoglobulin","volume":"36","author":"Rault","year":"1991","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archneur.1993.00540020015010","article-title":"Acute renal failure resulting from intravenous immunoglobulin therapy","volume":"50","author":"Tan","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib92","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib93","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0248-8663(98)80869-2","article-title":"A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)","volume":"19","author":"Cailleux","year":"1998","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib94","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/trf.12731","article-title":"Transfusion-related acute lung injury after transfusion of pooled immune globulin: a case report","volume":"54","author":"Quest","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib95","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12028-015-0115-z","article-title":"Transfusion-related acute lung injury after IVIG for myasthenic crisis","volume":"23","author":"Reddy","year":"2015","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1537-2995.2001.41020264.x","article-title":"Transfusion-related acute lung injury after the infusion of IVIG","volume":"41","author":"Rizk","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib97","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1423-0410.2012.01645.x","article-title":"Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient","volume":"104","author":"Stoclin","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib98","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib99","first-page":"213","article-title":"Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy","volume":"61","author":"Eijkhout","year":"2003","journal-title":"Neth J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2016.07.014_bib100","first-page":"111","article-title":"Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis","volume":"12","author":"Clemenz","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib101","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1246-7820(01)00109-4","article-title":"Insisting on intravenous polyvalent immunoglobulin therapy in polymyositis in spite of the occurrence of sever hemolytic anemia","volume":"8","author":"Ballot-Brossier","year":"2001","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib102","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2146\/ajhp060205","article-title":"Acute stroke with high-dose intravenous immune globulin","volume":"64","author":"White","year":"2007","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib103","first-page":"444","article-title":"Acute renal failure after intravenous immunoglobulin therapy","volume":"28","author":"Emilie","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib104","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/ndt\/16.7.1513","article-title":"Immunoglobulin as a risk factor for contrast media nephrotoxicity","volume":"16","author":"Bassilios","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib105","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1542\/peds.2007-1218","article-title":"Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content","volume":"121","author":"Manlhiot","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib106","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib107","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib108","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib109","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000441490","article-title":"Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases","volume":"7","author":"Cherin","year":"2015","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib111","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.autrev.2014.08.018","article-title":"Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib112","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0887-8994(95)00195-6","article-title":"Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin","volume":"13","author":"Vedanarayanan","year":"1995","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib113","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40273-015-0269-8","article-title":"Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand","volume":"33","author":"Bamrungsawad","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib114","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"issue":"Pt 8","key":"10.1016\/j.semarthrit.2016.07.014_bib115","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib116","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0161-5890(88)90088-0","article-title":"Immunoglobulin G dimer: an idiotype-anti-idiotype complex","volume":"25","author":"Tankersley","year":"1988","journal-title":"Mol Immunol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib118","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib119","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2007-03-077057","article-title":"Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells","volume":"110","author":"Tha-In","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib120","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.WNL.0000291619.17160.b8","article-title":"Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications","volume":"69","author":"Greenberg","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11926-011-0171-0","article-title":"Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease","volume":"13","author":"Quick","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib122","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.22558","article-title":"Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis","volume":"56","author":"Lopez de Padilla","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib123","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1172\/JCI109915","article-title":"Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G","volume":"66","author":"Kurlander","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib124","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib125","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1172\/JCI110158","article-title":"Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus","volume":"67","author":"Abdou","year":"1981","journal-title":"J Clin Invest"},{"issue":"2 Pt 2","key":"10.1016\/j.semarthrit.2016.07.014_bib126","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/0090-1229(89)90071-8","article-title":"Human IgG Fc receptors","volume":"53","author":"Anderson","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib128","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2353\/ajpath.2009.080422","article-title":"Role of regulatory T cells in a new mouse model of experimental autoimmune myositis","volume":"174","author":"Allenbach","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000093870","article-title":"Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders","volume":"55","author":"Hurnaus","year":"2006","journal-title":"Eur Neurol"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib131","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.07.014_bib132","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:02:20Z","timestamp":1568246540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216301457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0049017216301457"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.07.014","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}